SCHEMBL2094586

SCHEMBL2094586

COCCCc1ccc2scccc1-2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.44
DPP4 P27487 3/20 0.43
GAA P10253 5/20 0.40
KDM4E B2RXH2 6/20 0.39
ALDH1A1 P00352 5/20 0.39
HPGD P15428 4/20 0.39
MAPT P10636 3/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GLA P06280 3/20 0.37
HTT P42858 2/20 0.37
LMNA P02545 4/20 0.34
RAB9A P51151 1/20 0.34
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
ERN1 O75460 1/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5925319 0.74 LTA4H (0.48) LTA4HDPP4GAAKDM4EALDH1A1
SCHEMBL5539652 0.73 LTA4H (0.53) LTA4HDPP4GAAKDM4EALDH1A1
SCHEMBL5911240 0.72 TAAR1 (0.55) GAAALDH1A1MAPTLMNARAB9A
SCHEMBL10385976 0.71 LTA4H (0.60) LTA4HDPP4GAAKDM4EALDH1A1
SCHEMBL11742662 0.71 LTA4H (0.55) LTA4HGAAKDM4EALDH1A1
SCHEMBL5925309 0.70 LTA4H (0.54) LTA4HDPP4GAAKDM4EALDH1A1
SCHEMBL2092144 0.70 LTA4H (0.49) LTA4HDPP4GAAKDM4EALDH1A1
SCHEMBL29384385 0.69 DPP4 (0.47) DPP4GAAKDM4EL3MBTL1MEN1
SCHEMBL5925318 0.69 LTA4H (0.53) LTA4HDPP4GAAKDM4EALDH1A1
SCHEMBL2095475 0.69 GAA (0.38) GAAKDM4EALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 LTA4H 3093/4885DPP4 3073/4885GAA 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.